Gilead Sciences stock at EUR 142.09 pre-market: medicine developer rises 0.33 percent
Published on 10/28/2026 at 08:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEarnings date and business model
- Gilead Sciences develops medicines across virology, oncology and inflammation.
- The company lists its third-quarter 2026 earnings presentation for October 29, 2026, at 4:30 p.m. ET.
- Gilead Sciences stock trades pre-market at EUR 142.09 at 8:10 a.m. CET at Lang & Schwarz on October 28, 2026, 0.33 percent above the Xetra close of October 27, 2026.
Gilead Sciences develops medicines for serious diseases, with work spanning virology, oncology and inflammation, according to its website. Gilead Sciences stock trades pre-market at EUR 142.09 at 8:10 a.m. CET at Lang & Schwarz on October 28, 2026, 0.33 percent above the Xetra close of October 27, 2026 (EUR 141.62).
Ahead of the Xetra open
The indication is EUR 0.47 above the Xetra close. The bid was EUR 141.20 and the ask EUR 142.98, a spread of 1.25 percent. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
Business and calendar
Gilead Sciences operates as a biopharmaceutical company developing medicines for virology, oncology and inflammation. Its website lists a third-quarter 2026 earnings presentation for October 29, 2026, at 4:30 p.m. ET. Market context: Market report Nasdaq Composite.
